Evidence map›Paper›PMID 35683343›Full record

ArticleJournal of clinical medicine2022

Lack of Monitoring Is Associated with Risk of Acute Kidney Events among Patients with Inflammatory Bowel Disease.

Hamza Achit, Laurent Peyrin-Biroulet, Carole Ayav, Francis Guillemin, Luc Frimat

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Frontiers in pharmacology · 2026
    Article
  4. Article
  5. Review
  6. International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Effect and mechanism of total ginsenosides repairing SDS‑inducedExperimental and therapeutic medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hamza AchitClinical Epidemiology Centre CIC-1433 CHRU-Nancy, Inserm, Université de Lorraine, 54500 Vandoeuvre-les-Nancy, France.
Laurent Peyrin-BirouletInserm NGERE and Department of Gastroenterology, University Hospital of Nancy, Université de Lorraine, 54511 Vandoeuvre-les-Nancy, France.
Carole AyavClinical Epidemiology Centre CIC-1433 CHRU-Nancy, Inserm, Université de Lorraine, 54500 Vandoeuvre-les-Nancy, France.
Francis GuilleminClinical Epidemiology Centre CIC-1433 CHRU-Nancy, Inserm, Université de Lorraine, 54500 Vandoeuvre-les-Nancy, France.ORCID 0000-0002-9860-7024
Luc FrimatDepartment of Nephrology, University Hospital of Nancy, 54511 Vandoeuvre-les-Nancy, France.
Inserm · FRCentre Hospitalier Régional et Universitaire de Nancy · FR

Funding

Ferring Pharmaceuticals (France)
6 · The paper itself

Abstract

Background: Although the iatrogenic risk of kidney failure is infrequent with treatment for inflammatory bowel disease (IBD), the repercussions for the patient could be major. The aim of this study was to assess the incidence of kidney events in IBD and to examine the protective effect of kidney function monitoring. Methods: In the French National Health Insurance database, 94,363 patients had a diagnosis of IBD between January 2010 and December 2016. By using a survival model with time-dependent covariates, we analyzed the time from inclusion in this IBD cohort to the first hospitalization for acute kidney impairment (AKI) according to patient characteristics, comorbidities, IBD phenotype and presence of monitoring. Results: A total of 693 patients were hospitalized for AKI, with an incidence of 1.36/1000 person−years (95% confidence interval [CI] 1.26−1.47). The incidence of AKI was lower than those without 5-aminosalicylic acid (5-ASA) use. Patients with 5-ASA use rarely had any lack of monitoring as compared with those not under 5-ASA use (3% vs. 17%). On multivariate analysis, lack of monitoring was associated with a substantial risk of AKI (hazard ratio 3.96, 95% CI [3.20−4.90], p < 0.0001). Conclusions: Increased frequency of monitoring is essential to identify nephropathy at an early stage and avoid the progression to chronic kidney disease.

Indexed as

IBDmonitoringrenal involvement

Identifiers

PMID35683343
PMCPMC9181326
OpenAlexW4281567654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.